Related Experiment Videos
The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a
A Gulias-Herrero1, C A Aguilar-Salinas, F J Gómez-Pérez
1Department of Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico City.
Diabetes, Nutrition & Metabolism
|March 6, 2004
Summary
The combination of glyburide and metformin enhances blood sugar control by increasing insulin secretion, not insulin sensitivity. This combination therapy is more effective for achieving glycemic goals in type 2 diabetes patients.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management often requires combination therapy.
- Glyburide and metformin are commonly prescribed oral hypoglycemic agents.
- Understanding the synergistic mechanisms of combined therapies is crucial for optimizing T2DM treatment.
Purpose of the Study:
- To elucidate the mechanism of additive hypoglycemic effects of glyburide/metformin combination therapy.
- To compare the efficacy of glyburide, metformin, and their combination in achieving glycemic targets.
- To assess the impact of these treatments on insulin sensitivity and insulin secretion.
Main Methods:
- A double-blind, randomized, crossover clinical trial involving 20 patients with T2DM.
- Patients underwent a run-in period with a prescribed diet.
- Subsequent treatment periods involved glyburide, metformin, or the combination, with dosage adjustments to achieve fasting plasma glucose (FPG) < 7.7 mmol/l.
- Insulin sensitivity and secretion were measured using a minimal model and oral glucose tolerance test.
Main Results:
- The combination therapy achieved the glycemic goal in 10 out of 12 completers, significantly more than glyburide (5/12) or metformin (1/12) alone.
- The greatest reduction in HbA1c was observed with the combination therapy (9.0 +/- 2.1%) compared to glyburide (9.8 +/- 1.9%) and metformin (11 +/- 1.6%).
- The additive hypoglycemic effect was attributed to a significant increase in insulin secretion, with no significant change in insulin sensitivity.
Conclusions:
- The combination of glyburide and metformin demonstrates superior efficacy in improving glycemic control in T2DM patients.
- The enhanced hypoglycemic effect of the combination is primarily mediated by increased insulin secretion.
- This study highlights the importance of assessing both insulin sensitivity and secretion when evaluating combination diabetes therapies.